Company Profile

ABT insider trades (13 months) →

Today's multi-factor rank: 448 of 466 · see the ranking

Quant500 Scores

Momentum

3.4/10

Value

4.5/10

Growth

3.8/10

Quality

5.0/10

Multifactor

4.2/10

Market and Valuation

Price & Market

Prev Close Price:$102.23

Open:$101.83

Day's Low:$101.50

Day's High:$103.19

Bid / Ask:-

Market Cap:178.73B

Enterprise Value:205.32B

52-Week Range

52-Week Low:$81.97

52-Week High:$137.49

Current position in 52-week range

52w Low-52w High

50-Day Avg:$106.02

200-Day Avg:$105.20

Volume

Volume Today:27,048,914

Avg Volume (3m):10,328,804

Avg Volume (10d):9,706,430

52-Week Change:-24.57%

vs S&P 500, 52 weeks:-

Beta:0.59

Valuation Multiples

PER Trailing:33.10

PER Forward:16.92

PEG Ratio:1.88

Price / Book:3.47

Price / Sales (TTM):3.84

EV / Revenue:4.41

EV / EBITDA:17.58

Dividends

Current yield:2.47%

Annual Dividend Rate:$2.52

Dividend Trailing:$2.48

Yield Trailing:2.43%

5-Year Avg Yield:1.87%

Payout Ratio:78.96%

Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-

Fiscal Year (Next):-

Date Filter (Month):

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):46.58B

Gross Profit:26.48B

EBITDA:11.68B

Net Income (TTM):5.40B

Rev Growth (YoY):+13.00%

Earnings Growth (YoY):-47.50%

Quarterly earnings growth (YoY):-47.80%

Margins

Gross Margin:-

EBITDA Margin:-

Operating Margin:-

Net Margin:-

Per Share

EPS Trailing (TTM):-

EPS Forward (Est.):$6.07

Revenue Per Share:$26.76

Cash Per Share:-

Book Value:$29.54

Last Dividend:-

Ex-Dividend Date:-

Last Split:-

Balance Sheet & Liquidity

Total cash:5.60B

Total Debt:32.72B

Net Debt (Debt - Cash):27.12B

Debt / Equity:63.21%

Current Ratio:1.38

Quick Ratio:0.80

Cash Flows

Operating Cash Flow:9.91B

Free Cash Flow (FCF):7.21B

FCF Yield (FCF / Market Cap):-

Enterprise Value:205.32B

EV / Revenue:4.41

EV / EBITDA:17.58

Profitability

ROE (Return on Equity):10.58%

ROA (Return on Assets):5.33%

PER Trailing:33.10

PER Forward:16.92

Price / Book:3.47

PEG Ratio:1.88

52-Week Change:-24.57%

S&P 500 change, 52 weeks:+14.80%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$3.10

EPS Forward (Est.):$6.07

PER Forward:-

PEG Ratio:1.88

Growth and Margins

Earnings Growth YoY:-

Quarterly Earnings Growth YoY:-

Rev Growth YoY:-

Net Margin:-

Gross Margin:-

EBITDA Margin:-

Per Share

Revenue Per Share:$26.76

Cash Per Share:-

Book Value:$29.54

Cash Flows (TTM)

Free Cash Flow:7.21B

Operating Cash Flow:9.91B

EBITDA:11.68B

Total Revenue (TTM):46.58B

Net Income (TTM):5.40B

Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter	Period	Actual EPS	Estimated EPS	Difference	Surprise %	Currency

Ownership Structure

Ownership Distribution

% Insiders:-

% Institutional:-

% Inst. (of Float):-

No. of Institutions:-

Visual distribution

InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:1,741,813,154

Float (free shares):1,719,931,781

Short interest (shares):22,129,750

Short % of float:-

Short Ratio (days to cover):2.83

Short interest, prior month:-

Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-

Audit Risk:-

Board risk:-

Compensation Risk:-

Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization	Report Date	% Shares	No. Shares	Value (USD)	Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund	Report Date	% Shares	No. Shares	Value (USD)	Change %

Recent Insider Trades

Executive / Insider	Title	Date	Action	Shares

Options Chain

Expiration Date:

CALLS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

PUTS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

Abbott Laboratories (ABT) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type	Date	Official link
8-K	2026-08-20	View filing ↗
10-Q	2026-07-28	View filing ↗
8-K	2026-07-16	View filing ↗
11-K	2026-06-18	View filing ↗
SD	2026-05-27	View filing ↗
10-Q	2026-04-29	View filing ↗
8-K	2026-04-27	View filing ↗
S-8	2026-04-24	View filing ↗
8-K	2026-04-17	View filing ↗
8-K	2026-04-16	View filing ↗

Company and Executive Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

General Information

Headquarters:United States

City:Abbott Park

Employees:122,000

Sector:Healthcare

Industry:Medical Devices

Website:-

Key Executives

Name	Title	Age	Total pay
Mr. Robert B. Ford	Executive Chairman & CEO	51	4.43M
Mr. Philip P. Boudreau	CFO & Executive VP of Finance	52	2.10M
Mr. Daniel Gesua Sive Salvadori	Executive VP and Group President of Established Pharmaceuticals & Nutritional Products	46	1.52M
Mr. Christopher J. Scoggins	Executive Vice President of Diabetes Care	55	2.06M
Ms. Lisa D. Earnhardt	Executive VP & Group President of Medical Devices	55	2.39M
Ms. Sabina Ewing	Senior VP of Business & Technology Services and Chief Information Officer	51	-
Mr. Michael Comilla	Vice President of Investor Relations.	-	-
Erica L. Battaglia	VP and Chief Ethics & Compliance Officer	-	-

You have seen the engine room

Few finance sites let you get this far, and none we know of also shows you where its knowledge ends. If this way of working convinces you, the thing almost nobody catches in time can reach you by email: the big insider buys — executives and major shareholders putting in their own money — the same day they report them to the SEC, with the Form 4 linked. It takes three steps and none of them costs anything: create the account, confirm the email we send you, then switch the alert on in your profile (the icon at the top right). It starts off and it goes off again with the same click. Along the way all three are saved: your simulator portfolios, your personal portfolio and your Academy progress, synced across devices.

No card. No spam.

Abbott Laboratories (ABT): Quantitative Analysis

Name: Factor scores for Abbott Laboratories (ABT)
Creator: Quant500
License: https://quant500.com/legal

Abbott Laboratories (ABT) — Healthcare — Medical Devices. ABT is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, ABT has returned −16.6% against +12.2% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Sep 18, 2026.

ABT ranks 448 of 466 on today's multifactor score, and 54 of the 55 Healthcare companies that score. Its strongest factor is quality (Z -0.01, ranked 216 of 473); its weakest is momentum (Z -0.95, ranked 435 of 497). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

Factor	Z-Score	Rank
Multifactor	-0.482	448 of 466 ↓1
Momentum	-0.953	435 of 497 ↓5
Value	-0.275	300 of 494 ↓3
Quality	-0.007	216 of 473 =
Growth	-0.693	454 of 494 =

Market data

Metric	Value
Price	$102.61
Market Cap	178.73B
P/E	33.10
Revenue (last 12 months)	46.58B
Price / book	3.47
Book value per share	$29.54
52-week range	$81.97 – $137.49
Dividend yield	2.47%
Beta	0.59
Average volume	10,328,804
Shares outstanding	1.74B
Short interest (% of float)	1.43% (as of Aug 31, 2026)

When does ABT report earnings? 12 of its last 12, before the open →

What are ABT insiders doing? 59 transactions filed with the SEC, of them 5 buys and 10 sells, the last one on Sep 2, 2026 →

Data as of Sep 18, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

Company Profile

Market and Valuation

Price & Market

52-Week Range

Volume

Valuation Multiples

Dividends

Valuation Context

Financial Statements TTM (Trailing 12 Months)

Income Statement

Margins

Per Share

Balance Sheet & Liquidity

Cash Flows

Profitability

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

Growth and Margins

Per Share

Cash Flows (TTM)

EPS Surprise History - Last 4 Quarters

Ownership Structure

Ownership Distribution

Shares & Short Interest

Governance Score (1=Best, 10=Worst)

Top Institutional Holders

Top Mutual Funds

Recent Insider Trades

Options Chain

CALLS

PUTS

Sentiment Metrics

Expected move

Abbott Laboratories (ABT) SEC filings: 10-K, 10-Q and 8-K

Company and Executive Profile

General Information

Key Executives

You have seen the engine room

Abbott Laboratories (ABT): Quantitative Analysis

Factor scores

Market data